PD L1 News and Research

RSS
Durvalumab plus chemotherapy improved overall survival rate for mesothelioma patients

Durvalumab plus chemotherapy improved overall survival rate for mesothelioma patients

Roswell Park team proposes possible new strategy for treating pancreatic cancer

Roswell Park team proposes possible new strategy for treating pancreatic cancer

Innovative approach turns 'cold' tumors 'hot' to improve cancer immunotherapy

Innovative approach turns 'cold' tumors 'hot' to improve cancer immunotherapy

Patients with aggressive form of skin cancer can benefit from new type of immunotherapy

Patients with aggressive form of skin cancer can benefit from new type of immunotherapy

Combination therapy boosts the immune system's appetite for cancer

Combination therapy boosts the immune system's appetite for cancer

Researchers uncover how cancer cells don their invisibility cloaks

Researchers uncover how cancer cells don their invisibility cloaks

Tumors commandeer cell death pathway to avoid immune system attack after radiation

Tumors commandeer cell death pathway to avoid immune system attack after radiation

Study helps predict which ovarian cancer patients will not benefit from immune-PARP combo

Study helps predict which ovarian cancer patients will not benefit from immune-PARP combo

Study paves way for identifying ovarian cancer patients who will not benefit from combination therapy

Study paves way for identifying ovarian cancer patients who will not benefit from combination therapy

Levels of sBTLA proteins may be a marker of overall survival in patients with HCC

Levels of sBTLA proteins may be a marker of overall survival in patients with HCC

Breakthrough technology identifies proteins' nearest neighbors on cell surfaces

Breakthrough technology identifies proteins' nearest neighbors on cell surfaces

Combination of radiation and immunotherapy shows promise for advanced head and neck cancers

Combination of radiation and immunotherapy shows promise for advanced head and neck cancers

Biomarkers in blood samples can predict clinical response to immunotherapy in metastatic NSCLC

Biomarkers in blood samples can predict clinical response to immunotherapy in metastatic NSCLC

Administering immunotherapy alongside chemoradiation for advanced NSCLC appears to be safe and tolerable

Administering immunotherapy alongside chemoradiation for advanced NSCLC appears to be safe and tolerable

Global study shows long-term survival benefit for a subset of patients with advanced lung cancer

Global study shows long-term survival benefit for a subset of patients with advanced lung cancer

Researchers identify a protein that aids in colorectal cancer metastasis

Researchers identify a protein that aids in colorectal cancer metastasis

Scientists discover novel molecular pathway involved in immunotherapy response

Scientists discover novel molecular pathway involved in immunotherapy response

Researchers engineer probiotics to safely deliver immunotherapies to tumors

Researchers engineer probiotics to safely deliver immunotherapies to tumors

Avacta demonstrates initial proof-of-concept for TMAC drug conjugates in pre-clinical study

Avacta demonstrates initial proof-of-concept for TMAC drug conjugates in pre-clinical study

Community-based program enables donation of tumor tissue and blood samples for research

Community-based program enables donation of tumor tissue and blood samples for research

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.